113 related articles for article (PubMed ID: 36424257)
1. Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States.
Seeger JD; Amend KL; Turnbull BR; Zhou L; Marks MA; Velicer C; Saddier P
Vaccine; 2023 Mar; 41(11):1826-1833. PubMed ID: 36424257
[TBL] [Abstract][Full Text] [Related]
2. Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study.
Amend KL; Turnbull B; Zhou L; Marks MA; Velicer C; Saddier P; Seeger JD
Hum Vaccin Immunother; 2022 Nov; 18(5):2073750. PubMed ID: 35714277
[TBL] [Abstract][Full Text] [Related]
3. Vaccine initiation and 3-dose series completion of 4vHPV vaccine among US insured males 2012-2016.
Amend KL; Turnbull B; Zhou L; Marks MA; Velicer C; Saddier P; Seeger JD
Vaccine; 2022 Jan; 40(4):682-688. PubMed ID: 34794821
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
5. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization.
Ackerson B; Hechter R; Sidell M; Sy LS; Slezak J; Chao C; Patel N; Tseng HF; Jacobsen S
Vaccine; 2017 Feb; 35(6):897-902. PubMed ID: 28094077
[TBL] [Abstract][Full Text] [Related]
7. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
[TBL] [Abstract][Full Text] [Related]
8. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964
[TBL] [Abstract][Full Text] [Related]
9. Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants.
Murata S; Shirakawa M; Sugawara Y; Shuto M; Sawata M; Tanaka Y
Papillomavirus Res; 2020 Dec; 10():100205. PubMed ID: 32827835
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
11. A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States.
Bruce MG; Meites E; Bulkow L; Panicker G; Hurlburt D; Lecy D; Thompson G; Rudolph K; Unger ER; Hennessy T; Markowitz LE
Vaccine; 2020 Sep; 38(42):6585-6591. PubMed ID: 32814639
[TBL] [Abstract][Full Text] [Related]
12. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy.
Lipkind HS; Vazquez-Benitez G; Nordin JD; Romitti PA; Naleway AL; Klein NP; Hechter RC; Jackson ML; Hambidge SJ; Lee GM; Sukumaran L; Kharbanda EO
Obstet Gynecol; 2017 Sep; 130(3):599-608. PubMed ID: 28796684
[TBL] [Abstract][Full Text] [Related]
13. Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.
Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
Ann Intern Med; 2022 Jul; 175(7):918-926. PubMed ID: 35576590
[TBL] [Abstract][Full Text] [Related]
14. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.
Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C
Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009
[TBL] [Abstract][Full Text] [Related]
15. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
16. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
17. Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink.
Gee J; Sukumaran L; Weintraub E;
Vaccine; 2017 Oct; 35(43):5756-5758. PubMed ID: 28935469
[TBL] [Abstract][Full Text] [Related]
18. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
Petrosky E; Bocchini JA; Hariri S; Chesson H; Curtis CR; Saraiya M; Unger ER; Markowitz LE;
MMWR Morb Mortal Wkly Rep; 2015 Mar; 64(11):300-4. PubMed ID: 25811679
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
Shu Y; Yu Y; Ji Y; Zhang L; Li Y; Qin H; Huang Z; Ou Z; Huang M; Shen Q; Li Z; Hu M; Li C; Zhang G; Zhang J
Vaccine; 2022 Nov; 40(48):6947-6955. PubMed ID: 36283897
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
